Raoul Tibes

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
    Leena Chaudhuri
    Haematologica 99:688-96. 2014
  2. doi request reprint Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
    Raoul Tibes
    Mayo Clinic Cancer Center, NCI Designated Comprehensive Cancer Center, 13400 E, Shea Blvd, Scottsdale, AZ 85259, USA
    J Hematol Oncol 7:18. 2014
  3. doi request reprint Emerging drugs for polycythemia vera
    Raoul Tibes
    Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology and Medical Oncology, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Expert Opin Emerg Drugs 18:393-404. 2013
  4. doi request reprint JAK2 inhibitors in the treatment of myeloproliferative neoplasms
    Raoul Tibes
    Mayo Clinic, Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 21:1755-74. 2012
  5. doi request reprint Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms
    Raoul Tibes
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mol Diagn Ther 16:269-83. 2012
  6. doi request reprint RNAi screening of the kinome with cytarabine in leukemias
    Raoul Tibes
    Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 119:2863-72. 2012
  7. doi request reprint Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials
    Raoul Tibes
    Translational Genomics Research Institute and Virginia G Piper Cancer Center, Phoenix Scottsdale, Arizona, USA
    Cancer 117:3276-83. 2011
  8. doi request reprint JAK2 inhibitors and their impact in myeloproliferative neoplasms
    Holly L Geyer
    Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA
    Hematology 17:S129-32. 2012
  9. ncbi request reprint RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells
    Shilpi Arora
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Gynecol Oncol 118:220-7. 2010
  10. pmc Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
    Glen J Weiss
    Virginia G Piper Cancer Center at Scottsdale Healthcare VGPCC, Scottsdale, AZ 85258, USA
    Invest New Drugs 30:2334-43. 2012

Collaborators

Detail Information

Publications22

  1. ncbi request reprint CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
    Leena Chaudhuri
    Haematologica 99:688-96. 2014
    ..These results indicate that combined cell cycle checkpoint interference with MK1775/MK8776 warrants further investigation as a potential treatment for acute myeloid leukemia. ..
  2. doi request reprint Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
    Raoul Tibes
    Mayo Clinic Cancer Center, NCI Designated Comprehensive Cancer Center, 13400 E, Shea Blvd, Scottsdale, AZ 85259, USA
    J Hematol Oncol 7:18. 2014
    ..Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification. ..
  3. doi request reprint Emerging drugs for polycythemia vera
    Raoul Tibes
    Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology and Medical Oncology, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Expert Opin Emerg Drugs 18:393-404. 2013
    ..Polycythemia vera (PV) patients suffer from disease-related constitutional symptoms, cardiovascular complications and risk of transformation into myelofibrosis and acute leukemia...
  4. doi request reprint JAK2 inhibitors in the treatment of myeloproliferative neoplasms
    Raoul Tibes
    Mayo Clinic, Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 21:1755-74. 2012
    ..In addition, growth factor/cytokine stimulatory events activate JAK-STAT signaling independent of mutations...
  5. doi request reprint Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms
    Raoul Tibes
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mol Diagn Ther 16:269-83. 2012
    ..Future clinical development will focus on optimal combination partners and agents that target alternative mechanisms, deepen the response, and achieve molecular remissions...
  6. doi request reprint RNAi screening of the kinome with cytarabine in leukemias
    Raoul Tibes
    Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 119:2863-72. 2012
    ..Data from this first siRNA-kinome sensitizer screen suggests that inhibiting WEE1 in combination with Ara-C is a rational combination for the treatment of myeloid and lymphoid leukemias...
  7. doi request reprint Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials
    Raoul Tibes
    Translational Genomics Research Institute and Virginia G Piper Cancer Center, Phoenix Scottsdale, Arizona, USA
    Cancer 117:3276-83. 2011
    ..The authors conducted a prospective study examining patients' willingness to undergo such tests and the number of tests the patients would tolerate...
  8. doi request reprint JAK2 inhibitors and their impact in myeloproliferative neoplasms
    Holly L Geyer
    Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA
    Hematology 17:S129-32. 2012
    ....
  9. ncbi request reprint RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells
    Shilpi Arora
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Gynecol Oncol 118:220-7. 2010
    ..In order to improve cisplatin response in ovarian cancer cells, we utilized a high-throughput RNAi screening to identify kinase modulators...
  10. pmc Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
    Glen J Weiss
    Virginia G Piper Cancer Center at Scottsdale Healthcare VGPCC, Scottsdale, AZ 85258, USA
    Invest New Drugs 30:2334-43. 2012
    ..This phase I trial assessed the safety, maximally tolerated dose (MTD) and pharmacokinetics of TRKA/CDK inhibitor PHA-848125AC in adult patients with advanced/metastatic solid tumors...
  11. doi request reprint A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors
    Gayle S Jameson
    Virginia G Piper Cancer Center at Scottsdale Healthcare VGPCC TGen, Scottsdale, AZ, USA
    Clin Cancer Res 19:268-78. 2013
    ..This study was designed to establish the maximum tolerated dose (MTD) and to evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol...
  12. doi request reprint Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials
    Mitesh J Borad
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Invest New Drugs 31:1056-65. 2013
    ..57 % (96 of 830). Uniform criteria and guidelines for selection of QTc formulae need to be developed. Formulae-specific QTc thresholds also need to be specified...
  13. doi request reprint Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
    Glen J Weiss
    Virginia G Piper Cancer Center at Scottsdale Healthcare TGen, Scottsdale, Arizona 85238, USA
    Clin Cancer Res 17:2997-3004. 2011
    ....
  14. doi request reprint Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    Madappa N Kundranda
    Division of Hematology Oncology, Department of Internal Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Hematol Malig Rep 7:78-86. 2012
    ..This review focuses on the latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population...
  15. doi request reprint Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Raoul Tibes
    Department of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Lymphoma 52:1178-87. 2011
    ..Alternative agents (with alternative targets), used either alone or in combination, might perhaps further augment the spectrum of efficacy and therapeutic options for MPNs...
  16. doi request reprint A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Cancer Chemother Pharmacol 71:463-71. 2013
    ..gov identifier: NCT00894894) in patients with solid tumors refractory to prior therapies or for which no standard therapy existed...
  17. pmc The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials
    Mitesh J Borad
    1 Department of Internal Medicine, Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ
    J Cancer 3:345-53. 2012
    ..The most common medications discontinued were herbal, proton pump inhibitors, selective serotonin reuptake inhibitor anti-depressants, and non-steroidal anti-inflammatory drugs...
  18. doi request reprint Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
    Daniel D Von Hoff
    Translational Genomics Research Institute and Scottsdale Healthcare, Scottsdale, AZ, USA
    N Engl J Med 361:1164-72. 2009
    ..In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug...
  19. pmc RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
    Shilpi Arora
    Pharmaceutical Genomic Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Mol Cancer 9:218. 2010
    ..As part of novel target discovery in Ewing's sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and survival of Ewing's sarcoma cells...
  20. doi request reprint Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents
    Bing Z Carter
    Affiliations of authors Section of Molecular Hematology and Therapy, Department of Leukemia BZC, PYM, DHM, YS, YQ, hm, ROJ, TM, SMK, MA and Department of Bioinformatics and Computational Biology HY, Krc, University of Texas M D Anderson Cancer Center, Houston, TX Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ JMB, RT
    J Natl Cancer Inst 106:djt440. 2014
    ....
  21. doi request reprint Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
    Chad Cherington
    Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Res 36:1147-51. 2012
    ..We conclude that MPN-BP can be cured by allo-SCT in a significant percentage of patients, but that adequate leukemic clearance prior to allo-SCT offers an optimal outcome...
  22. doi request reprint Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques
    Raoul Tibes
    Mayo Clinic, Scottsdale, AZ 85259, United States
    Leuk Res 36:664-71. 2012
    ..This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints...